Culture

Low fitness linked to higher psoriasis risk later in life

image: In a major register-based study, scientists at University of Gothenburg, Sweden, have now demonstrated a connection between inferior physical fitness in young adults and elevated risk of the autoimmune disease psoriasis. For the male recruits to compulsory military training who were rated as the least fit, the risk of developing psoriasis later was 35 percent higher than for the fittest.

Image: 
Anders Dahlberg

In a major register-based study, scientists at University of Gothenburg, Sweden, have now demonstrated a connection between inferior physical fitness in young adults and elevated risk of the autoimmune disease psoriasis. For the male recruits to compulsory military training who were rated as the least fit, the risk of developing psoriasis later was 35 percent higher than for the fittest.

The study was based on data on more than 1.2 million men conscripted, aged 18, into the Swedish Armed Forces between the years 1968 and 2005. During the enrollment process, all these young men underwent the same fitness test on an exercise bicycle. The researchers divided the data, according to how fit the men were, into three levels (low, medium, and high fitness). They then merged the data with other registers, using Sweden's National Patient Register to obtain diagnostic codes for psoriasis and the joint disease psoriatic arthritis. The men who had already received one of these diagnoses before conscription were excluded from the study.

Later in life, between the ages of 37 and 51, just over 23,000 of the conscripts developed psoriasis or psoriatic arthritis. In the low-fitness group, 2.5 percent developed one or both of these diseases, while only 1.7 percent in the high-fitness group did so. In calculating this risk differential, the scientists adjusted for other risk factors, such as body mass index (BMI).

Association not causal

Thus, the less fit the men were when they were recruited, the higher the proportion of them who later fell ill with psoriasis or psoriatic arthritis. In the low-fitness group, the risk of developing psoriasis was 35 percent higher, and that of developing psoriatic arthritis 44 percent higher, than in the high-fitness group.

"We show that there's an association between lower fitness and raised risk of developing psoriasis and psoriatic arthritis, but we don't show a causal connection. So we can't say that these health conditions can be prevented by exercising," says the study's first author Marta Laskowski, a doctoral student in dermatology at the University of Gothenburg and resident physician (specialist trainee) at Sahlgrenska University Hospital.

Group in need of monitoring

The group of men who were least fit was also the smallest: just under 48,000 or 3.9 percent of all the conscripts in the study. This is a group that healthcare services should try to monitor regularly.

"Low fitness was already known to boost the risk of incurring cardiovascular disease, and psoriasis as such is linked to raised cardiovascular disease risk, too. The results from our study confirm the reasons for assessing people's fitness early in life, to identify individuals at a higher risk for adverse health outcomes later in life," Laskowski says.

Previous research has indicated that, in general, people with psoriasis are less fit than those without it who engage in an equal amount of physical activity. However, the reasons for this difference have not been fully clarified.

"One weakness of our study is that we weren't been able to monitor the trends of the men's fitness during the intervening years, between their conscription and the disease onset. We're also lacking data on smoking, which is a known risk factor for psoriasis," Laskowski explains.

Scaly skin patches

Some 300,000 Swedes have psoriasis in a mild, moderate, or severe form. It is a chronic, systemic inflammatory disease that affects women as often as men. What triggers its onset is not entirely clear, but heredity is known to play a large part in combination with external factors. The most common type, plaque psoriasis, causes reddened, flaking, and itchy skin lesions ("plaques").

Psoriasis sufferers also often have other diseases. Some 30 percent get the inflammatory joint condition known as psoriatic arthritis. Examples of other known comorbidities are obesity, cardiovascular disease, diabetes, and depression.

In recent years, treatment options have substantially improved. Today, besides ointments with local effects, there are drugs that have systemic effects. Recent years have also seen the emergence of efficacious biological agents that modulate the signaling cascade in the inflammatory process that drives psoriasis.

Credit: 
University of Gothenburg

UK government must urgently rethink lateral flow test roll out, warn experts

UK government plans to widen the roll out of the Innova lateral flow test without supporting evidence risks serious harm, warn experts in The BMJ today.

More than £1 billion have been spent on purchasing lateral flow tests, but Professor Jon Deeks and colleagues argue that the public is being misled about their accuracy, as well as the risks and implications of false negative results, and they call on the government urgently to change course.

Mass testing may be helpful and necessary in certain circumstances if delivered to high quality, they explain, but the Innova lateral flow test is not fit for this purpose.

For example, in the Liverpool pilot study, 60% of infected symptomless people went undetected, including 33% of those with high viral loads who are at highest risk of infecting others. And among students in Birmingham, only 3% of those who would have tested positive on the "gold standard" PCR test were detected.

Yet the government continues to claim that the Innova test detects 77%, they write, and has championed the use of negative tests to enable visiting relatives in care homes, returning to work or staying in school, despite known exposure to an infectious case.

The government is also relying on mathematical models rather than real world evaluations of testing. They argue that the models used rely on flawed assumptions about test performance and how results will affect human behaviour. "Together they tend to overestimate potential benefits and underestimate potential harms."

No one questions the need for evidence based approaches to covid 19 treatments and vaccines. Why then, in the face of so little evidence of benefit, and so much evidence of poor test performance, is the government pushing the rollout, they ask?

It seems at least plausible that this is because hundreds of millions of Innova testing kits were purchased before it was known how they would perform in people without symptoms and when administered by less than expert hands, they suggest. These tests are now sitting in warehouses around the country.

Given all of the above, they call on the government at least to pause the rollout of rapid asymptomatic testing using the Innova test, including its use in care homes, schools, communities and self-testing by untrained people at home, until clearer messaging on the risks of negative results can be developed.

They also ask for full documentation relating to Innova's approval, and for publication of full reports for all studies and models of the Innova test.

What's more, information materials should be revised to make explicit the extremely poor sensitivity of the Innova test for community and self-use among those without symptoms; and the aims, outcomes and full costings of mass testing of keyworkers, schoolchildren, university students, and care home visitors should be reviewed, they add.

"Finally, since testing makes no difference unless followed by appropriate action, the UK needs a national scheme to enable self-isolation of cases and contacts through support, including financial and accommodation for those in need," they conclude.

Credit: 
BMJ Group

Fossils' soft tissues helping to solve puzzle that vexed Darwin

image: Researchers carrying out fieldwork in Namibia

Image: 
Rachel Wood

Remarkably well-preserved fossils are helping scientists unravel a mystery about the origins of early animals that puzzled Charles Darwin.

Analysis of the 547 million-year-old remains has enabled researchers to trace the ancestry of some of the world's earliest animals further back than ever before.

Their study has uncovered the first known link between animals that evolved during the so-called Cambrian Explosion some 540 million-years-ago and one of their early ancestors.

Until recently, little was known about the origins of animals that evolved during the Cambrian event because of a lack of well-preserved fossil evidence.

The mysterious origins of animals that evolved at this time - when the diversity of life on Earth increased rapidly, giving rise to almost all modern-day animal groups - baffled 19th century naturalist Charles Darwin. It is often referred to as Darwin's dilemma.

Prior to the new study, it had proven difficult to trace links with earlier animals because their soft tissues - which provide vital clues about the animals' ancestry - almost always break down over time.

During fieldwork in Namibia, scientists from the University of Edinburgh unearthed the fossil remains of tiny animals - known as Namacalathus - that resemble a pin cushion attached to a short stalk.

Using an x-ray imaging technique, the team found some of the animals' soft tissues immaculately preserved inside the fossils by a metallic mineral called pyrite. Until now, scientists had only ever identified skeletal remains of Namacalathus.

Studying the soft tissues - and comparing them with those in animals that evolved later - revealed that Namacalathus was an early ancestor of species that appeared during the Cambrian Explosion. Among them are types of prehistoric worms and molluscs.

The study, published in the journal Science Advances, was funded by the Natural Environment Research Council. The work also involved a researcher from Lomonosov Moscow State University, Russia.

Professor Rachel Wood, of the University of Edinburgh's School of GeoSciences, said: "These are exceptional fossils, which give us a glimpse into the biological affinity of some of the oldest animals.

"They help us trace the roots of the Cambrian Explosion and the origin of modern animal groups. Such preservation opens up many new avenues of research into the history of life which was previously not possible."

Credit: 
University of Edinburgh

DiosCURE to develop highly specific single-chain antibodies against SARS-CoV-2

image: Logo for DiosCURE

Image: 
© DiosCURE Therapeutics

Core technology includes promising bivalent single-domain antibodies simultaneously targeting two surface structures of the viral spike protein.

Lead candidates DIOS-202 and DIOS-203 are engineered for high potency and their potential to avoid the emergence of escape mutants.

DIOS-202 and DIOS-203 entered into accelerated development to initiate clinical studies later this year.

BONN, Germany, January 12, 2021 - DiosCURE SE announced a publication in Science describing its core technology of multivalent single-chain antibodies with a unique molecular mode-of-action to inactivate SARS-CoV-2 virions. An international team led by scientists at the University of Bonn developed and characterized the lead candidates, which are exclusively licensed by DiosCURE.

"This global pandemic requires an arsenal of therapeutic and preventative tools and our lead candidates will allow us to contribute to what will be an ongoing battle," stated Klaus Wilgenbus, Chief Executive Officer at DiosCURE. "DiosCURE was established with the goal of developing novel, best-in-class immunotherapies to protect a significant population which will remain at risk, including exposed healthcare workers, immunocompromised patients, non-responders to vaccines and patients experiencing post-acute COVID-19 syndrome. The data now published provides a solid foundation to continue our development efforts with the goal of entering the clinic later this year."

The company's lead candidates, DIOS-202 and DIOS-203, are synergistic combinations of single-domain antibodies derived from camelid heavy chain-only antibodies. These next-generation immunotherapies against SARS-CoV-2 were designed based on detailed structural information of the antibodies' interaction with its viral target protein and result from functional and evolutionary experiments. The discovery and promising early preclinical data were published in an article in Science entitled "Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape" on January 12, 2021. The study details the identification of DiosCURE's lead candidates out of millions of potential structures, as well as the rational design of multivalent constructs, which increased neutralizing activity more than 100-fold. Preclinical studies demonstrated that DIOS-202 and DIOS-203 selectively target two distinct epitopes of the SARS-CoV-2 spike protein at once, which largely prevents the emergence of escape mutants. The dual targeting induces the premature activation of the fusion machinery, rendering the virions non-infectious. These discoveries were accomplished through a collaborative effort of research groups at the University Hospital of the University of Bonn (led by the Institute of Innate Immunity and the Core Facility Nanobodies), The Scripps Research Institute and the Karolinska Institutet.

The lead candidates are expected to be highly efficacious, well-tolerated, cost-efficient in production and are amenable to a wide range of clinical applications. As immunotherapies, DIOS-202 and DIOS-203 are suitable as prophylactic and to treat infected patients to avoid severe COVID-19 disease.

"The structure-based multivalent single-chain antibodies we discovered have strong potential for clinical applications. This is owed to their highly potent neutralizing activity and in-built protection from the rapid emergence of escape mutants. The emergence of SARS-CoV-2 escape mutants will remain an ongoing challenge in this pandemic, and novel therapies are urgently needed to address this problem," stated Eicke Latz, Director of the Institute of Innate Immunity at the University of Bonn, co-founder and Board member of DiosCURE. "Our understanding of the short- and long-term consequences of SARS-CoV-2 is rapidly evolving, and rational therapeutics targeting the virus are needed to curb the potentially devastating consequences of COVID-19."

Credit: 
Trophic Communications

Healthcare Nutrition Council leads the way on medical food discussions

image: Healthcare Nutrition Council Logo

Image: 
Healthcare Nutrition Council

While most people are able to eat a normal diet, many of those managing distinct nutritional requirements related to a disease or health condition rely on medical foods. Medical foods help patients meet their nutritional needs, often improving nutritional and health outcomes and quality of life. A recent publication in Current Developments in Nutrition, titled "Medical Foods: Science, Regulation, and Practical Aspects. Summary of a Workshop," shares the historical and regulatory context of medical foods and perspectives on their role in the future.

Medical foods help patients manage their nutritional needs, yet it can be very difficult for patients to have access to them. In August 2019, the Healthcare Nutrition Council (HNC), in partnership with the American Society for Nutrition (ASN), held the Medical Foods Workshop: Science, Regulation, and Practical Aspects. The workshop discussions focused on:

Patient and healthcare professional considerations for and benefits from medical foods.

Opportunities for product innovation and future research. Real-world examples were discussed for enteral tube feeding, surgery and trauma, intractable epilepsy, diabetes, renal disease, and inflammatory bowel disease.

The role of clinical guidelines for developing and use of medical foods.

The use of medical foods in clinical practice under medical supervision.

The statutory term distinctive nutritional requirements.

The regulatory term modification of the diet alone.

Differentiation of medical foods from foods for special dietary use.

"The objectives of our workshop were to advance the dialogue on the scientific and regulatory status of medical foods in the U.S., drive consensus on terms and definitions for medical foods, and ultimately help improve patient access to these important products," said Robert Rankin, Executive Director of HNC. "It was extremely important that the workshop included a variety of stakeholders, encompassing patients, clinicians, government officials, and the medical food industry. We have more work ahead to improve the landscape for medical foods, assuring that the regulatory framework fosters research, innovation, and development for these important products as well as assuring patients have access to products which improve their clinical care."

Credit: 
Kellen Communications - NY

Another common cold virus? Modeling SARS-CoV-2's progress through the ages

image: Simulation shown with R0=4.
Faster transmission results in a quicker transition to the endemic state but more total deaths.
Social distancing saves lives, delays endemicity and allows crucial time for vaccine roll-out.
Vaccination speeds up the transition to the endemic state and reduces the death toll.

Image: 
Jennie Lavine

What is the endgame for SARS-CoV-2, the virus that is causing worldwide devastation? If it becomes endemic -- circulating in the general population -- and most people are exposed in childhood, SARS-CoV-2 may join the ranks of mild cold-causing coronaviruses that currently circulate in humans, according to a model developed by Emory and Penn State scientists.

The model, published January 12 in Science, draws upon studies of the four common cold coronaviruses and SARS-CoV-1. For those viruses, the term "herd immunity" is incomplete and possibly misleading, says postdoctoral fellow Jennie Lavine, PhD, first author of the Science paper.

The four common cold-causing coronaviruses have been circulating in humans for a long time and almost everyone is infected at a young age - younger than measles before a vaccine was available. Natural infection in childhood provides immunity that protects people later in life against severe disease, but it doesn't prevent periodic reinfection, says Lavine.

"Reinfection is possible within one year, but even if it occurs, symptoms are mild and the virus is cleared from the body more quickly," she says. "It highlights the need to tease apart the components of immunity to SARS-CoV-2. How long does immunity that prevents pathology last, and how long does immunity that prevents transmission last? Those durations may be very different."

Studies are now emerging that provide concrete data on how long antibodies and immune cells against SARS-CoV-2 last after infection, Lavine says. However, researchers are still figuring out how those components translate to protection against disease or transmission.

"Overall, we're asking: how does SARS-CoV-2 compare to other viruses such as seasonal influenza or respiratory syncytial virus," she says. "This model assumes immunity to SARS-CoV-2 works similar to other human coronaviruses. We don't really know what it would be like if someone got one of the other coronaviruses for the first time as an adult, rather than as a child."

The model predicts that the infection fatality ratio for SARS-CoV-2 may fall below that of seasonal influenza (0.1 percent), once an endemic steady-state is reached.

"We are in uncharted territory, but a key take-home message from the study is that immunological indicators suggest that fatality rates and the critical need for broad-scale vaccination may wane in the near term, so maximum effort should be on weathering this virgin pandemic enroute to endemicity," said Ottar Bjornstad, Distinguished Professor of Entomology and Biology and J. Lloyd & Dorothy Foehr Huck Chair of Epidemiology, Penn State.

Lavine developed the model, together with Bjornstad and Rustom Antia, PhD, Samuel C. Dobbs professor of biology at Emory University and Emory Vaccine Center.

A safe and effective vaccine against COVID-19 could save hundreds of thousands of lives in the first year or two of vaccine roll-out, but continued mass vaccination may be less critical once SARS-CoV-2 becomes endemic, the authors say. Targeted vaccination in vulnerable subpopulations may still save lives, they say.

Another implication is: during the transition to endemicity, that using symptoms only as a surveillance tool to look for infections and curb the virus' spread will become more difficult. Thus, widely available testing may become particularly important during vaccine roll-out to protect vulnerable populations, the authors point out.

So far, the available data on SARS-CoV-2 infection in infants and young children suggest that severity is generally mild and mortality is low. There are exceptions on the individual level, with some experiencing rare complications such as MIS-C (multisystem inflammatory syndrome in children). In contrast, if SARS-CoV-2 infection in childhood were to become more severe - like MERS-CoV (Middle East respiratory syndrome-related coronavirus) - routine vaccination programs will be still necessary, the authors say.

Credit: 
Emory Health Sciences

New promising antibodies against SARS-CoV-2

image: Cell culture plates with stained cells, in which virus replication can be quantified by the ‚holes' that virus infection causes in the cell lawn.

Image: 
© Volker Lannert/ University of Bonn

Antibodies are an important weapon in the immune system's defense against infections. They bind to the surface structures of bacteria or viruses and prevent their replication. One strategy in the fight against disease is therefore to produce effective antibodies in large quantities and inject them into the patients. The outgoing US President Donald Trump probably owes his rapid recovery to this method. However, the antibodies used to treat him have a complex structure, do not penetrate very deeply into the tissue and may cause unwanted complications. Moreover, producing antibodies is difficult and time-consuming. They are therefore probably not suitable for widespread use.

Mass production in yeast or bacteria

"We focus on another group of molecules, the nanobodies," explains Dr. Florian Schmidt, who heads an Emmy Noether group on this promising new field of research at the University of Bonn's Institute of Innate Immunity. "Nanobodies are antibody fragments that are so simple that they can be produced by bacteria or yeast, which is less expensive."

However, the immune system produces an almost infinite number of different antibodies, and they all recognize different target structures. Only very few of them are for example capable of defeating the SARS coronavirus-2. Finding these antibodies is like searching for a single grain of sand on Germany's Baltic coast. "We first injected a surface protein of the coronavirus into an alpaca and a llama," Schmidt explains. "Their immune system then produces mainly antibodies directed against this virus. In addition to complex normal antibodies, llamas and alpacas also produce a simpler antibody variant that can serve as the basis for nanobodies."

A few weeks later, the researchers took a blood sample from the animals, from which they extracted the genetic information of produced antibodies. This "library" still contained millions of different construction plans. In a complex process, they extracted those that recognize an important structure on the surface of the coronavirus, the spike protein. "Altogether we obtained dozens of nanobodies, which we then analyzed further," explains Dr. Paul-Albert König, head of the Core Facility Nanobodies at the Medical Faculty of the University of Bonn and lead author of the study.

Four out of several million

Four molecules actually proved to be effective against the pathogen in cell cultures. "Using X-ray structures and electron microscopy analyses, we were furthermore able to show how they interact with the spike protein of the virus," explains König. This work was done in the research groups around Martin Hällberg (Karolinska Institutet, Sweden) and Nicholas Wu as well as Ian Wilson (Scripps Research Institute, USA). The spike protein is crucial for the infection: It acts like a velcro fastener with which the pathogen attaches to the attacked cell. Next, the velcro changes its structure: It discards the component that is important for attachment and mediates fusion of the virus envelope with the cell. "Nanobodies also appear to trigger this structural change before the virus encounters its target cell - an unexpected and novel mode of action," says König. "The change is likely to be irreversible; the virus is therefore no longer able to bind to host cells and infect them."

The researchers also exploit another major advantage of nanobodies over antibodies: Their simple structure allows straight forward combinations to form molecules that can be several hundred times more effective. "We have fused two nanobodies that target different parts of the spike protein," explains König. "This variant was highly effective in cell culture. Furthermore, we were able to show that this drastically reduces the probability of the virus to become resistant to the active agent through escape mutations." The researchers are convinced that the molecules may be developed into a novel and promising therapeutic option.

Dioscure Therapeutics, a spin-off of the University of Bonn, will test the nanobodies in clinical studies. The success of the project is mainly based on the excellent cooperation of the participating research groups at the University with national and international cooperation partners, emphasizes Florian Schmidt, who is also a member of the Immunosensation2 Cluster of Excellence at the University of Bonn.

Credit: 
University of Bonn

New small antibodies show promising effects against COVID-19 infection

Researchers at Karolinska Institutet in Sweden have developed, in collaboration with researchers in Germany and the U.S., new small antibodies, also known as nanobodies, which prevent the SARS-CoV-2 coronavirus from entering human cells. The research study, published in Science, shows that a combined nanobody had a particularly good effect - even if the virus mutated. According to the researchers, the nanobodies have the potential to be developed into a treatment for COVID-19.

Specific proteins, spike proteins, on the surface of the SARS-CoV-2 coronavirus help the virus infect host cells. Therefore, antibodies that block the spike proteins and prevent them from binding to the cell can be a way to stop infection.

From the perspective of potential therapeutic interventions, small fragments of antibodies, referred to as single-domain antibodies (sdAb) or nanobodies, may be a better alternative than regular antibodies. That is because nanobodies are significantly smaller. They are therefore able to bind to the virus in more places than regular antibodies. Nanobodies also have greater stability and are easier to produce cost-effectively on a large scale.

Researchers at Karolinska Institutet are now publishing, in collaboration with researchers at the University of Bonn in Germany and the Scripps Research Institute in California, a study describing new nanobodies against SARS-CoV-2 infection.

"What is uniquely special here is that we have stitched together nanobodies that bind to two different places on the spike protein of the virus," explains Martin Hällberg, researcher at the Department of Cell and Molecular Biology at Karolinska Institutet, and one of the research study's corresponding authors.

"This combination variant binds better than individual nanobodies and is exceptionally effective in blocking the virus' ability to spread between human cells in cell culture."

Additionally, the combined nano-antibodies worked even when tested on a virus variant that mutates extremely quickly.

"This means that the risk is very small that the virus would become resistant to these combined nanobodies," notes Martin Hällberg.

To generate the nanobodies, alpacas and llamas - animals whose immune systems naturally produce both antibodies and nanobodies - were vaccinated with the spike protein of the coronavirus. Among the nanobodies generated by the animals, the researchers selected the best binders. Among these, four were identified as showing an exceptional ability to block the virus' ability to spread among human cultured cells.

The research group at Karolinska Institutet then used electron cryomicroscopy (cryo-EM) to study in detail how the various nanobodies bind to the virus' spike protein. Thanks to their structural knowledge, they were able to propose suitable protein links to bind different nanobodies together into combinations relevant for research, as well as provide a possible explanation for the mechanism of how the antibodies neutralise the virus.

"My 'favourite' is the nanobody from the llama," Martin Hällberg says. "It binds directly over the surface where the virus binds the host cell receptor ACE2, and the nanobody also shares a large majority of the amino acids critical for binding with ACE2. What this means is that the virus will have an extremely difficult time mutating extensively on that surface and at the same time being able to bind ACE2. A variant where this llama antibody is linked to one of the antibodies from alpaca was a fox trap that the virus never managed to get out of in our experiments."

The researchers now hope that their nanobodies will be able to be developed into a drug treatment as a complement to a vaccination against COVID-19.

"It possibly could be used clinically for those already ill, or for prevention for individuals who for one reason or another cannot be vaccinated, or who have a weakened immune system, and therefore may not form a sufficiently strong immune response after a vaccination," explains Martin Hällberg.

Dioscure Therapeutics, a spin-off company from the University of Bonn, will be conducting further testing of the nanobodies in clinical trials. The researchers at Karolinska Institutet will make attempts to improve the binding further by changing individual building blocks in the nanobodies.

The research was funded by the Swedish Research Council and the Knut and Alice Wallenberg Foundation, as well as by research funders in Germany and the U.S.

Credit: 
Karolinska Institutet

Strategy tested in mice protects against SARS-CoV-2 & coronaviruses that represent human threats

An immunization strategy tested in mice protects against infection from SARS-CoV-2, as well as from potentially emerging animal coronaviruses, researchers say. The approach could be "used as described or easily adapted" to provide defense against newly discovered zoonotic coronaviruses. In the last 20 years, three betacoronaviruses have caused devastating disease in humans. The global pandemic caused by the latest such virus, SARS-CoV-2, highlights the need to protect against other strains that could present a threat to humans, possibly through a pan-coronavirus vaccine. To support related efforts, Alexander A. Cohen and colleagues used a "plug and display" approach to make a series of nanoparticles displaying the receptor-binding domain (RBD) of either SARS-CoV-2 alone ("homotypic nanoparticles") or the SARS-CoV-2 RBD along with a diverse set of RBDs from bat and pangolin betacoronaviruses that represent threats to humans ("mosaic nanoparticles"). In studies in mice, immunization with mosaic nanoparticles did not reduce immune response compared with immunization by a homotypic nanoparticle. What's more, mosaic nanoparticles generated cross-reactive immune responses in mice after one injection, whereas such responses required prime and boost injections in the case of the homotypic particle. The mosaic nanoparticles also elicited antibodies that, beyond recognizing the strains displayed, recognized mismatched strains, the authors say. Studying IgG antibodies from COVID-19 plasma donors, Cohen et al. found they exhibited little to no recognition of coronaviruses other than SARS-CoV-2, suggesting SARS-CoV-2-infection-induced immunity in humans would be unlikely to be protective against an outbreak of a new zoonotic coronavirus. This is yet another indication of the need to develop a vaccine to protect against emerging coronaviruses, they say. The results suggest mosaic nanoparticles as a candidate vaccine to protect against COVID-19 and other emerging coronaviruses with human spillover potential, write Cohen and team.

Credit: 
American Association for the Advancement of Science (AAAS)

Museum scientists: Prepare for next pandemic now by preserving animal specimens in natural history

It's been more than a year since the first cases were identified in China, yet the exact origins of the COVID-19 pandemic remain a mystery. Though strong evidence suggests that the responsible coronavirus originated in bats, how and when it crossed from wildlife into humans is unknown.

In a study published online Jan.12 in the journal mBio, an international team of 15 biologists say this lack of clarity has exposed a glaring weakness in the current approach to pandemic surveillance and response worldwide.

In most recent studies of animal-borne pathogens with the potential to spread to humans, known as zoonotic pathogens, physical specimens of suspected wildlife hosts were not preserved. The practice of collecting and archiving specimens believed to harbor a virus, bacteria or parasite that's under investigation is called host vouchering.

"Vouchered specimens should be considered the gold standard in host-pathogen studies and a key part of pandemic preparedness," said Cody Thompson, co-lead author of the mBio paper and mammal collections manager at the University of Michigan Museum of Zoology.

"But host vouchering has effectively been nonexistent in most recent zoonotic pathogen studies, and the lack of this essential information has limited our ability to respond to the current COVID-19 pandemic," said Thompson, who is also an assistant research scientist in the U-M Department of Ecology and Evolutionary Biology.

To fill this knowledge gap, Thompson and his co-authors urge researchers who conduct host-pathogen studies to adopt vouchering practices and to collaborate with natural history museums to permanently archive host specimens, along with their tissue and microbiological samples.

The authors of the mBio article include experts in mammalogy, bat biology, microbiology, natural history, ornithology, bioinformatics, parasitology and host-pathogen biology. Most of them have ties to natural history museums.

"In essence, vouchering provides both an offensive mechanism for pandemic prevention--by expanding the surveillance of wildlife hosts and associated pathogens--and a defensive mechanism by providing a verifiable archive for baseline comparisons," said study co-lead author Kendra Phelps of EcoHealth Alliance, a global nonprofit that works to prevent pandemics and promote wildlife conservation.

"This problem becomes especially critical in navigating novel viral zoonoses, such as the COVID-19 pandemic, where it is necessary for the scientific community to swiftly and efficiently leverage its collective knowledge and resources to effectively understand and contain the spread of novel pathogens at a time when lockdown restrictions hamper on-going sampling efforts."

The emergence of infectious diseases attributed to novel pathogens that "spill over" from animal populations into humans has increased in recent decades.

The COVID-19 pandemic, in particular, has demonstrated that a previously unknown pathogen can emerge from wildlife species and threaten public health on a global scale within months. Experts from the World Health Organization are expected to arrive in China this week for a long-anticipated investigation into the pandemic's origins.

During spillover events, vouchered specimens in museum collections and biorepositories can help disease sleuths quickly track a pathogen to its source in the wild. The authors of the mBio study highlight three examples--yellow fever, hantaviruses and parasitic worms--of host-pathogen research that successfully incorporated natural history collections into collaborative research programs.

Vouchered host specimens can help answer fundamental biological, ecological and evolutionary questions about host-pathogen dynamics. The specimens allow for scientific replicability, they help ensure correct taxonomic identification of the host species, they establish a baseline for future studies, and they provide biological samples that can extend research as new technologies emerge.

At the same time, archiving host specimens in natural history collections provides access to a "vast, largely untapped biodiversity infrastructure" within museums, according to the authors of the mBio paper.

"We need to think of natural history collections as resources for preventing future pandemics, with the potential to promote powerful interdisciplinary and historical approaches to studying emerging zoonotic pathogens," said U-M's Thompson.

As part of their study, the mBio authors surveyed more than 100 microbiologists--bacteriologists, parasitologists and virologists--from around the world to assess their vouchering practices when conducting host-pathogen research.

Fewer than half said they voucher host specimens from which microbiological samples were lethally collected. In the cases where host specimens were obtained, most were deposited in the collections of natural history museums.

To help foster collaborations between microbiologists and curators of natural history collections, the authors also provide recommendations for integrating vouchering techniques and archiving of microbiological samples into host-pathogen studies.

Credit: 
University of Michigan

New technology reveals fast and slow twitch muscle fibers respond differently to exercise

Exercising regularly is one of the best defences against metabolic diseases, such as obesity and diabetes - but why? It's a question that scientists are still struggling to answer. While exercising changes the molecular behaviour of muscles, it's not well understood how these molecular changes improve metabolic health.

Scientists at the University of Copenhagen have now developed a new technology that allows researchers to study muscle biology on a more detailed level - and hopefully find some new answers. They extracted 'fast' and 'slow' twitch muscle fibers from freeze-dried muscle samples that were taken before and after 12 weeks of cycling exercise training. Their comprehensive analysis of the protein expression of the fibers provides new evidence that the fiber types respond differently to exercise training.

The research, which was published in Nature Communications, also demonstrates the untapped potential of freeze-dried samples that are located in freezers around the world.

"Metabolic disorders and several muscle diseases are known to affect or spare specific fiber types, therefore detailed investigation of specific fiber types is crucial. Previous studies involving large-scale protein analysis of muscle fibers required isolation of single muscle fibers from freshly obtained muscle biopsies. Since isolation of muscle fiber is time consuming, this approach has its inherent limitations. Our method enables muscle fiber analysis of already collected muscle biopsies as well as paves the new way for future studies," says Associate Professor Atul Deshmukh from the Novo Nordisk Foundation Center for Basic Metabolic Research (CBMR) at the University of Copenhagen.

Messy and confusing muscle samples

Skeletal muscle contains tiny fibers that can be categorised as either fast or slow twitch. Simply put, fast twitch fibers create explosive energy but get tired quickly, while slow twitch fibers are less energetic but have more endurance. Most people have an even number of both types in their muscles, but the ratio can vary widely between people. This means that exercise may benefit people differently, depending on this ratio.

In a muscle, thousands of fibers are bundled together by connective tissue and interspersed with a range of cell types with a supporting function. Because of all these different cell types, scientists can struggle to interpret the results of a whole muscle sample, and connect observed changes to specific cell types.

Understanding the potential of studying individual fibers, Atul Deshmukh teamed up with Professor Matthias Mann from the Novo Nordisk Foundation Center for Protein Research, and the Wojtaszewski Group from the Department of Nutrition, Exercise and Sports, both at the University of Copenhagen.

Honing in on muscle fibers

They recruited healthy individuals for 12 weeks of endurance exercise training and collected muscle samples before and after exercise, which were then freeze-dried. They then extracted fast and slow twitch muscle fibers from the samples and carried out high-resolution mass spectometry-based proteomics - a tool that allows scientists to measure thousands of proteins simultaneously in the different samples.

They identified more than 4,000 different proteins in the samples, and discovered that exercise training changed the expression of hundreds of different proteins in both fast and slow twitch fiber-types. Importantly, they discovered differences to the protein expression of the two fiber-types after exercise, which demonstrates that fast and slow twitch muscle respond differently.

"Our method can be scaled for high-throughput analysis of hundreds of individual muscle fibers from a single biopsy. Coupling this approach with the modern high sensitivity mass spectrometer may help to understand the fiber type heterogeneity in healthy and diseased skeletal muscle," says Associate Professor Atul Deshmukh from the Novo Nordisk Foundation Center for Basic Metabolic Research (CBMR) at the University of Copenhagen.

Drugs that don't accidentally target the heart

By mass, skeletal muscle is the largest organ in the body and even small changes can have tremendous impact on whole body metabolism. Skeletal muscle is therefore an interesting pharmacological target tissue with great potential in treatment of metabolic diseases. One challenge is however to avoid side effects in heart muscle, for example, which consists of specialized fibers with some similarities to slow twitch skeletal muscle fibers.

"Thus, our fiber-type specific protein repository is a first step toward identification of skeletal muscle proteins that are specific for fast twitch fibers, allowing drug targeting and delivery to this specific fiber type and potentially avoiding side effects in the heart," says Professor Jørgen Wojtaszewski from the Department of Nutrition, Exercise and Sports at the University of Copenhagen .

Credit: 
University of Copenhagen - The Faculty of Health and Medical Sciences

Hospitals must help their own COVID long-haulers recover, experts argue

BOSTON -- By mid-November, the Centers for Disease Control and Prevention had reported that 218,439 health care workers in the U.S. had been infected with COVID-19 -- a likely underestimate due to incomplete data from states. About 3% to 4% of health care personnel who recover from coronavirus infection are expected to become "COVID long-haulers" as they cope with debilitating symptoms 12 to 18 months after the acute stage of the infection clears.

"As COVID-19 surges again, hospitals are facing a shortage of skilled frontline providers who can meet the relentless demands of caring for these patients," says Zeina N. Chemali, MD, MPH, a psychiatrist and neurologist at Massachusetts General Hospital (MGH) and senior author of an article in Lancet Respiratory Medicine on the challenges of health care workers who are COVID long-haulers. "Providers struggling with post-COVID complications will further strain the health care system unless medical institutions step up to support those who have sacrificed their health during the pandemic." Chemali directs MGH's McCance Center for Brain Health and the neuropsychiatry clinic, which treat COVID survivors with lingering symptoms.

Long-term complications of COVID can affect multiple organs in the body. Some people suffer neuropsychiatric complaints, such as overwhelming fatigue, brain fog, persistent headaches, altered sleep, anxiety, post-traumatic stress disorder and difficulty concentrating. They may also have cardiopulmonary symptoms -- fatigue after exertion, shortness of breath, persistent cough, heart arrhythmias, fluctuating blood pressure and fainting. Currently there are no curative treatments for post-COVID syndromes; therapy focuses on alleviating symptoms and coping strategies. Long-term complications of COVID can occur even in mild cases of the virus.

Chemali and her colleagues are calling for medical institutions to support and promote the safe return to work for all health care workers disabled from lingering symptoms of COVID. Current national return-to-work guidelines focus primarily on health care workers' infection status, leaving institutions to establish their own policies or for employees to opt for medical or disability leave. While some institutions have made accommodations for health care personnel as they return to work post-COVID, the measures may not apply to all affected workers, exacerbating existing social inequities. In addition, the culture of medicine elevates duty to patients over personal needs, leaving behind the wellness of its workforce.

The authors recommend that multidisciplinary teams at medical institutions be charged with devising back-to-work strategies for health care workers with long-term COVID symptoms. These strategies might include a gradual reintroduction into the work force, limiting shifts so natural circadian rhythms aren't disrupted, mandating frequent breaks and reducing workloads to prevent fatigue, and partnering with other providers to provide oversight during complex tasks and to share clinical responsibilities.

In addition, the authors are advocating for Congress to acknowledge the health issues and needs of long-hauler health care providers and for the new Biden administration to create funding to support health care workers as they recover from COVID. Previous U.S. government initiatives, such as the Coronavirus Aid, Relief, and Economic Security (CARES) Act, provided financial support to medical practices and hospitals struggling during the pandemic, but essential hospital workers disabled by the virus didn't individually benefit from the funding, says Chemali.

Medical institutions and society have a moral obligation to support health care veterans of the COVID war, says Chemali, who studies mental health and neurological disorders among refugees and in people living in war zones. "Whether frontline providers are taking care of people in war zones or in hospitals filled with patients with COVID, they are working in dangerous, very uncertain and stressful environments," says Chemali. "And yet they continue to perform their mission despite being overworked and burned out, which decreases their resilience and perhaps their immunity to the virus itself. We need to do better by health care workers who get sick with COVID. If we don't help survivors of COVID recover and return to work as providers, institutions risk losing even more of their skilled personnel, who will succumb to the exhaustion and stress caused by this relentless COVID tsunami."

Credit: 
Massachusetts General Hospital

Study finds risk factors linked to COVID-19 mental health impacts for college students

A study of students at seven public universities across the United States has identified risk factors that may place students at higher risk for negative psychological impacts related to the COVID-19 pandemic. Factors associated with greater risk of negative impacts include the amount of time students spend on screens each day, their gender, age and other characteristics.

Research has shown many college students faced significant mental health challenges going into the COVID-19 pandemic, and experts say the pandemic has added new stressors. The findings, published in the journal PLOS ONE, could help experts tailor services to better support students. The observational study was drawn from a survey of more than 2,100 undergraduate and graduate students in the spring of 2020, when the students at all the universities included in the study had shifted to studying remotely.

"The pandemic is problematic for everyone, and we know that it's especially problematic for students who are eager to experience the unique social atmosphere that college life has to offer," said study co-author Lincoln Larson, associate professor of parks, recreation and tourism management at North Carolina State University. "COVID-19 has thrown a wrench into all of that. Our study found the pandemic is clearly taking a significant psychological toll on students."

In the survey, researchers asked students about the extent to which they felt negative emotions like fear, guilt, irritability, stress and worry when they thought about COVID-19. Researchers also asked open-ended question about how their feelings have changed since the start of the pandemic.

Students most commonly said in the open-ended responses that they felt unmotivated, anxious, stressed and isolated. More than 21 percent of students said they experienced feelings related to lack of motivation: some thought it was difficult to concentrate and others felt unproductive or that they were procrastinating. More than 17 percent said they felt anxious.

When the researchers analyzed students' responses to questions about the extent to which they felt specific emotions, they found 45 percent of students across the seven universities experienced a high risk of psychological impacts. Forty percent of students had a moderate psychological impact risk, and just 14 percent of students were in the low risk category.

The researchers used the data to identify characteristics linked to greater psychological impact from the pandemic. Female students, younger students aged 18 to 24 years, students who had more than eight hours per day of screen time and students who knew someone who contracted COVID-19 were more likely to experience negative psychological impacts from the pandemic, researchers found when they analyzed all of the factors that contributed to mental health risk.

"Our study documents that nearly half of college students were at a severe handicap in terms of their quality of life, education and social relationships because of their mental health during the early stages of the pandemic," said the study's lead author Matthew Browning, an assistant professor at Clemson University. "It also identifies the risk factors that can help colleges and universities target interventions or messaging to encourage these students to come and get help."

The researchers saw that in some cases, students' race or ethnicity and socio-economic status were linked to risk for high psychological impact when those factors were studied independently of others. Specifically, students who identified as Asian were at greater risk, as well as students with fair or poor health.

Spending two or more hours of daily time outdoors was linked to lower mental health impacts before adjusting for other risk factors. Researchers said those potential risk factors need further study.

Overall, they believe the findings could help universities tailor services for students.

"Campus leaders can devise creative interventions to facilitate social interactions and help students adopt more growth-oriented mindsets that turn this unique challenge into an opportunity," Larson said. "While some screen time may be necessary in this era of social distancing, there are still ways for students to connect, get outdoors and be active."

Across the nation, mental health experts have been working to address a growing prevalence of mental health issues among college and university students. A survey of college presidents in the fall of 2020 from the American Council on Education, in partnership with TIAA Institute, found the top two most pressing issues for presidents of four-year institutions were mental health of students and mental health of faculty and staff. On top of existing mental health challenges, the pandemic created new stressors, including increased isolation, said Monica Osburn, executive director of the North Carolina State University Counseling Center.

"Mental health was a significant challenge before COVID, and it absolutely exacerbated what students are feeling," Osburn said. "If you think about it from a developmental perspective, there are many developmental milestones that this group is experiencing loss around."

The NC State Counseling Center is offering virtual counseling appointments for students. For students who don't need counseling but are seeking support, NC State Prevention Services staff are also offering "drop-in" spaces for students to connect to talk about nature, racial and ethnic trauma, expression and the arts. There are also groups for students affected by loss of a loved one, and for coping with COVID-19. NC State Wellness and Recreation also offers online fitness classes and mind-body sessions for students.

"Any good data is helpful data because it gives us areas to target to be able to support students to make change," Osburn said of the study findings. "We want students to know it's OK to ask for help. We want them to reach out to get support. We want them to know: You don't have to go at it alone."

Credit: 
North Carolina State University

New humanized mouse model provides insight into immunotherapy resistance

image: Dr. Rajasekharan Somasundaram

Image: 
The Wistar Institute

PHILADELPHIA -- (Jan. 12, 2021) -- Scientists at The Wistar Institute have created an advanced humanized immune system mouse model that allows them to examine resistance to immune checkpoint blockade therapies in melanoma. It has revealed a central role for mast cells. These findings were published today in the journal Nature Communications.

Checkpoint inhibitors revolutionized therapeutic options for advanced melanoma. However, only a fraction of patients respond to this treatment and some relapse due to reemergence of therapy-resistant lesions.

"To better understand why some cancers do not respond or become resistant to checkpoint therapies, we need more preclinical models that mimic the human tumor immune environment," said Rajasekharan Somasundaram, Ph.D., a member of The Wistar Institute Melanoma Research Center, who is the first and corresponding author of the paper.

Due to critical differences in the murine and human immune systems, mouse models do not allow the study of immune mechanisms that are uniquely human. "Humanized" mouse models are widely used to mimic the human immune system in mice.

Wistar's new humanized mouse model relies upon transplanted human stem cells and tissues that have been uniquely engineered to produce combinations of human cytokines that result in a more physiologically relevant model system for evaluating new immuno-oncology therapies and effective treatments targeting the tumor microenvironment.

"Our novel humanized mouse model has a longer life span and allowed us to study treatment responses to immunotherapies after human tumor transplant," said Somasundaram, who was part of a Wistar team led by Meenhard Herlyn, D.V.M., D.Sc., professor in The Wistar Institute Cancer Center, director of The Wistar Institute Melanoma Research Center, and a co-senior author on the study.

Researchers transplanted human metastatic melanoma cell lines into their humanized mouse model and treated them with anti-PD-1 antibody therapy. By studying immune cell infiltration into the tumors, Somasundaram and colleagues observed an abundance of infiltrated mast cells in anti-PD-1-treated tumors. Mast cells are an immune cell found throughout the body, especially in the skin and mucosa, where they serve as a first line of defense against pathogens. In samples from melanoma patients receiving immune checkpoint therapies, the team saw the same higher abundance of mast cells in non-responding tumors.

The authors showed that combining anti-PD-1 therapy with small molecule inhibitors able to deplete mast cells caused complete regression of tumors in mice and prolonged survival in comparison with mice receiving either treatment. Importantly, mice that reached remission did not show any signs of recurrence for four weeks after cessation of therapy and developed memory T cell response against melanoma tumors.

"Our results suggest that mast cells are associated with resistance to anti-PD-1 therapy, and that depleting mast cells is beneficial to immune checkpoint therapy responses," said Herlyn. "This warrants further investigation into the development of new combined immunotherapy approaches with small molecule inhibitors for the treatment of melanoma patients."

Credit: 
The Wistar Institute

Scientists reveal how gut microbes can influence bone strength in mice

Gut microbes passed from female mice to their offspring, or shared between mice that live together, may influence the animals' bone mass, says a new study published today in eLife.

The findings suggest that treatments which alter the gut microbiome could help improve bone structure or treat conditions that weaken bones, such as osteoporosis.

"Genetics account for most of the variability in human bone density, but non-genetic factors such as gut microbes may also play a role," says lead author Abdul Malik Tyagi, Assistant Staff Scientist at the Division of Endocrinology, Metabolism, and Lipids at Emory Microbiome Research Center, Emory University, Georgia, US. "We wanted to investigate the influence of the microbiome on skeletal growth and bone mass development."

To do this, Tyagi and colleagues studied mice that lacked any gut microbes. They transferred fecal material containing a gut microbe called segmented filamentous bacteria (SFB), which stimulates the breakdown of bone, into the animals. Their studies revealed that the offspring of the SFB-treated mice were colonised with these bacteria at birth and had poorer bone structure than identical mice that lacked SFB.

Additionally, mice that lived with others carrying SFB became colonised with the bacteria within four weeks, and developed poorer bone structure as a result. "Our work shows that microbes can be either inherited or transmitted between individuals and significantly affects skeletal development in the animals," Tyagi says.

"Further studies are now needed to determine if the same is true in humans," adds senior author Roberto Pacifici, Garland Herndon Professor of Medicine, and Director of the Division of Endocrinology, Metabolism, and Lipids, at Emory University. "If it is, then it could be possible to develop therapies that change the gut microbiome early in life to allow for healthy skeletal growth.

"It would also suggest the need for caution in the current use of fecal transplants to treat other conditions in patients, to ensure that bone-weakening bacteria aren't inadvertently introduced," Pacifici concludes.

Credit: 
eLife